Pharmacological Inhibition of Ferroptosis Attenuates Experimental Abdominal Aortic Aneurysm Formation

Jonathan R Krebs1, Paolo Bellotti1, Walker Ueland1

  • 1Department of Surgery (J.R.K., P.B., W.U., J.A.C.V., D.J.M.K., S.S., G.S., J.B.H., A.A., M.S., G.C., A.K.S., G.R.U.), University of Florida, Gainesville.

Abstract

Insights

This study reveals that inhibiting ferroptosis, a form of cell death, in macrophages can reduce abdominal aortic aneurysm (AAA) development and associated vascular inflammation.

Area of Science:

  • Cardiovascular Biology
  • Cell Death Mechanisms
  • Vascular Remodeling

Background:

  • Abdominal aortic aneurysm (AAA) pathogenesis involves vascular inflammation, thrombosis, and cell death, leading to aortic remodeling.
  • Ferroptosis, an iron-mediated cell death, plays a role in macrophage-driven aortic inflammation and remodeling in AAA formation.

Purpose of the Study:

  • To investigate the role of ferroptosis in macrophages during AAA formation.
  • To determine if inhibiting ferroptosis can mitigate AAA development and associated pathological changes.

Main Methods:

  • Single-cell RNA sequencing of human AAA tissue.
  • Induction of AAA in wild-type mice using elastase models, with and without liproxstatin-1 (ferroptosis inhibitor).
  • Analysis of aortic diameter, cytokine expression, histology, ferroptosis markers, and lipid profiles; in vitro studies on macrophage-smooth muscle cell crosstalk.

Main Results:

  • Significant differences in ferroptosis-related genes in macrophages from human AAA tissues.
  • Liproxstatin-1 treatment attenuated aortic diameter, inflammation, immune cell infiltration, and elastic fiber disruption in mice.
  • Lipidomic analysis revealed altered ceramide and intact lipid species levels in AAA tissue.
  • In vitro studies showed liproxstatin-1 mitigated macrophage ferroptosis, MMP9 expression, and crosstalk with smooth muscle cells via MMP2.

Conclusions:

  • Pharmacological inhibition of ferroptosis by liproxstatin-1 mitigates macrophage-dependent ferroptosis.
  • This inhibition contributes to reduced aortic inflammation and remodeling in AAA formation.

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...